Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Search
Heart Failure
Heart Failure
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Stroke Prevention in AF
Stroke Prevention in AF
Science Stories
Science Stories
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Dedifferentiated liposarcoma (DDLPS)
An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
IPF treatment discussions
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
Welcome to Innovation at Boehringer Ingelheim
Watch our video and find out more about innovation at Boehringer Ingelheim.
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Pradaxa®
Prevention of strokes and blood clots in patients with abnormal heart rhythm (atrial fibrillation). Primary prevention of venous thrombo-embolic events (VTE) in adults after elective total hip or knee replacement surgery. Treatment of deep vein throm
Lung Diseases
Lung Diseases
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Careers beyond borders
Careers beyond borders
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Are you missing the bigger picture on mental health?
Revolutionizing our approach to serious mental health conditions is crucial for tailored care, placing those with lived experience at the center.
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones